EGFRHER1

EGFRHER1 is not a standard gene symbol in major public databases and does not correspond to a separately defined gene. The term most likely refers to the epidermal growth factor receptor (EGFR), which is also known as ERBB1 or HER1. In some datasets or older literature, nonstandard labels such as “EGFR-HER1” may appear, but there is no widely recognized entity distinct from EGFR/HER1.

EGFR/HER1 is a receptor tyrosine kinase encoded by the EGFR gene, located on chromosome 7p11.2. The protein has an extracellular ligand-binding domain, a single transmembrane helix, and an intracellular tyrosine kinase domain. Ligand binding induces receptor dimerization and autophosphorylation, activating downstream signaling pathways including RAS-RAF-MEK-ERK, PI3K-AKT, and JAK-STAT. Through these pathways, EGFR regulates cell proliferation, survival, differentiation, and migration.

Clinical significance is well established in oncology. EGFR is overexpressed or amplified in several cancers, notably glioblastoma, colorectal cancer, and non-small cell lung cancer. Activating EGFR mutations (for example, certain exon 19 deletions and L858R in NSCLC) predict sensitivity to EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib, erlotinib, afatinib, and osimertinib. Resistance mechanisms include the T790M mutation and alternative pathway activation. EGFR-targeted monoclonal antibodies, like cetuximab and panitumumab, are used in colorectal and head and neck cancers with appropriate EGFR status.

Nomenclature can vary; EGFR is also called ERBB1 or HER1. When encountering “EGFRHER1,” verification against authoritative databases is recommended to confirm it refers to EGFR/HER1 rather than a nonstandard fusion or artefact.